JP2012530778A - ロサルタンカルボン酸を含有する薬学組成物及びその製造方法 - Google Patents
ロサルタンカルボン酸を含有する薬学組成物及びその製造方法 Download PDFInfo
- Publication number
- JP2012530778A JP2012530778A JP2012517397A JP2012517397A JP2012530778A JP 2012530778 A JP2012530778 A JP 2012530778A JP 2012517397 A JP2012517397 A JP 2012517397A JP 2012517397 A JP2012517397 A JP 2012517397A JP 2012530778 A JP2012530778 A JP 2012530778A
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- pharmaceutical composition
- polyethylene glycol
- water
- soluble polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title abstract description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 24
- 229920001223 polyethylene glycol Polymers 0.000 claims description 24
- 229920003169 water-soluble polymer Polymers 0.000 claims description 22
- 239000007962 solid dispersion Substances 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 2
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 23
- 238000010828 elution Methods 0.000 description 43
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003006 anti-agglomeration agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- HLKZFSVWBQSKKH-UHFFFAOYSA-N but-3-enoic acid;1-ethenylpyrrolidin-2-one Chemical compound OC(=O)CC=C.C=CN1CCCC1=O HLKZFSVWBQSKKH-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【選択図】図1
Description
下記表1の成分及び含量の比率に従ってロサルタンカルボン酸及びその他の添加剤を単純混合し、カプセルに充填して比較例1及び実施例1ないし4を製造した。
製造した比較例1を用いてpH 1.2緩衝液(塩化ナトリウム2.0gに塩酸7.0mlを入れ、精製水を加えて1リットルにする)、pH 4.0緩衝液(0.05mol/L酢酸液と0.05mol/L酢酸ナトリウム液との混合液(41:9)を製造し、pH 4.0に調節する)、pH 6.8緩衝液(0.2mol/Lリン酸二水素カリウム試液250mlに、0.2mol/L水酸化ナトリウム試液118ml及び水を入れて1リットルにする)及び精製水で溶出実験を行った。溶出実験ではパドル法を用いた。溶出媒質の量は900mlであって、パドルの回転速度は50rpmであった。時間(分)による溶出率(%)を下記表2に示した。
比較例1と同様の方式で、実施例1ないし4のpH 1.2緩衝液における溶出を評価した。その結果を下記表3に示した。
下記表4の成分及び含量の比率によってロサルタンカルボン酸と水溶性高分子とを含む固体分散体を製造した。
比較例1と同様の方式で、実施例5ないし10のpH 1.2緩衝液における溶出を評価した。その結果を表5に示した。
比較例1と同様の方式で、実施例9の様々な溶出媒質における溶出を評価した。その結果を表6に示した。
実施例9と同様に、1錠当たり20mgのロサルタンカルボン酸を含む錠剤を製造し、それを用いて吸収評価実験を行った。被実験数は6人であり、ロサルタンカルボン酸を含有する錠剤を水240mLと共に空腹時に投薬した。ロサルタンカルボン酸の血中濃度はLC/MS/MSを用いて測定し、その結果は図1に示した。
Claims (6)
- 前記水溶性高分子が、ポリエチレングリコール、ポリオキシエチレン‐ポリオキシプロピレン共重合体、ポリビニルアルコール‐ポリエチレングリコール共重合体、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、ビニルピロリドン‐ビニルアセテート共重合体、ポリビニルアルコール、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシエチルメチルセルロース、ポリビニルアセテート、ポリアルケンオキサイド、ポリアルケングリコール、ジエチルアミノアセテート、アミノアルキルメタクリレート共重合体、アルギン酸ナトリウム及びゼラチンからなる群より選択されたいずれか1つ以上であることを特徴とする請求項1に記載の薬学組成物。
- 前記水溶性高分子が、ポリエチレングリコール、ポリオキシエチレン‐ポリオキシプロピレン共重合体及びポリビニルアルコール‐ポリエチレングリコール共重合体からなる群より選択されたいずれか1つ以上を含むことを特徴とする請求項2に記載の薬学組成物。
- 前記水溶性高分子が、ポリエチレングリコール、ポリオキシエチレン‐ポリオキシプロピレン共重合体及びポリビニルアルコール‐ポリエチレングリコール共重合体からなる群より選択されたいずれか1つ以上のポリエチレングリコール系水溶性高分子と、ポリエチレングリコール系水溶性高分子以外の他の水溶性高分子との混合物であることを特徴とする請求項3に記載の薬学組成物。
- 前記固体分散体が、シリカ、クロスポビドン、またはこれらの混合物を含むことを特徴とする請求項1ないし請求項4のうちいずれか1項に記載の薬学組成物。
- 前記薬学組成物が、シリカ、クロスポビドン、またはこれらの混合物を含むことを特徴とする請求項1ないし請求項4のうちいずれか1項に記載の薬学組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090057054 | 2009-06-25 | ||
KR10-2009-0057054 | 2009-06-25 | ||
PCT/KR2010/004152 WO2010151080A2 (ko) | 2009-06-25 | 2010-06-25 | 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012530778A true JP2012530778A (ja) | 2012-12-06 |
JP5442116B2 JP5442116B2 (ja) | 2014-03-12 |
Family
ID=43387070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012517397A Expired - Fee Related JP5442116B2 (ja) | 2009-06-25 | 2010-06-25 | ロサルタンカルボン酸を含有する薬学組成物及びその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120095067A1 (ja) |
EP (1) | EP2446879B1 (ja) |
JP (1) | JP5442116B2 (ja) |
KR (1) | KR101817986B1 (ja) |
CN (1) | CN102802611B (ja) |
WO (1) | WO2010151080A2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007051109A (ja) * | 2005-08-19 | 2007-03-01 | Taiyo Yakuhin Kogyo Kk | 圧縮成型製剤 |
WO2007055183A1 (ja) * | 2005-11-08 | 2007-05-18 | Astellas Pharma Inc. | ベンゼン誘導体又はその塩 |
JP2008536929A (ja) * | 2005-04-18 | 2008-09-11 | ルビコン・リサーチ・ピーヴィーティー・エルティーディー | 生体強化組成物 |
JP2008538561A (ja) * | 2005-04-20 | 2008-10-30 | メルク エンド カムパニー インコーポレーテッド | アンジオテンシンii受容体アンタゴニスト |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2238975A1 (en) * | 1995-12-12 | 1997-06-19 | Merck & Co., Inc. | New use for losartan |
AU747110B2 (en) * | 1998-02-25 | 2002-05-09 | Merck & Co., Inc. | Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
ITMI20050551A1 (it) * | 2005-04-01 | 2006-10-02 | Dipharma Spa | Forma cristallina alfa di losartan potassio |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
US20100008956A1 (en) * | 2008-07-08 | 2010-01-14 | Jie Du | Composition and combinations of carboxylic acid losartan in dosage forms |
-
2010
- 2010-06-25 WO PCT/KR2010/004152 patent/WO2010151080A2/ko active Application Filing
- 2010-06-25 CN CN201080028788.7A patent/CN102802611B/zh not_active Expired - Fee Related
- 2010-06-25 KR KR1020117030206A patent/KR101817986B1/ko active IP Right Grant
- 2010-06-25 US US13/380,266 patent/US20120095067A1/en not_active Abandoned
- 2010-06-25 JP JP2012517397A patent/JP5442116B2/ja not_active Expired - Fee Related
- 2010-06-25 EP EP10792362.5A patent/EP2446879B1/en not_active Not-in-force
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536929A (ja) * | 2005-04-18 | 2008-09-11 | ルビコン・リサーチ・ピーヴィーティー・エルティーディー | 生体強化組成物 |
JP2008538561A (ja) * | 2005-04-20 | 2008-10-30 | メルク エンド カムパニー インコーポレーテッド | アンジオテンシンii受容体アンタゴニスト |
JP2007051109A (ja) * | 2005-08-19 | 2007-03-01 | Taiyo Yakuhin Kogyo Kk | 圧縮成型製剤 |
WO2007055183A1 (ja) * | 2005-11-08 | 2007-05-18 | Astellas Pharma Inc. | ベンゼン誘導体又はその塩 |
Also Published As
Publication number | Publication date |
---|---|
JP5442116B2 (ja) | 2014-03-12 |
KR20120111935A (ko) | 2012-10-11 |
EP2446879B1 (en) | 2014-02-12 |
EP2446879A4 (en) | 2012-11-21 |
WO2010151080A3 (ko) | 2011-05-19 |
EP2446879A2 (en) | 2012-05-02 |
CN102802611B (zh) | 2014-11-12 |
KR101817986B1 (ko) | 2018-01-16 |
WO2010151080A2 (ko) | 2010-12-29 |
CN102802611A (zh) | 2012-11-28 |
US20120095067A1 (en) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4852423B2 (ja) | 固体の経口投与可能な医薬組成物の製造方法 | |
JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
US20200330600A1 (en) | Pharmaceutical composition | |
CN103550165B (zh) | 一种含有利伐沙班的药物组合物及其制备方法 | |
JP7172997B2 (ja) | エンザルタミドを含有する経口投与用医薬組成物 | |
TW201206903A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzi midazol-2-yl]-1H-quinolin-2-one lactate monohydrate | |
TW201127377A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
JP5714562B2 (ja) | 経口用徐放性固形製剤 | |
JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
JP6293315B2 (ja) | アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物 | |
JP5124286B2 (ja) | 徐放性製剤およびその製造方法 | |
JP6639024B2 (ja) | 化学的な安定性を改善した、非晶質体ソリフェナシン含有製剤 | |
JP2020532544A (ja) | デュタステリドを含む固形製剤およびその製造方法 | |
JP2020518614A (ja) | 改善された持続放出性高充填薬物組成物 | |
CN102406622A (zh) | 一种托伐普坦的固体制剂 | |
EP1797872A1 (en) | Telmisartan-containing pharmaceutical compositions for oral intake | |
WO2010026597A1 (en) | Oral dosage forms of linezolid and processes for their preparation | |
JP5442116B2 (ja) | ロサルタンカルボン酸を含有する薬学組成物及びその製造方法 | |
CN113476415A (zh) | 一种盐酸鲁拉西酮片剂及其制备方法 | |
JP2022514040A (ja) | 耐酸性に優れたタムスロシン塩酸塩含有医薬組成物及びその製造方法 | |
TWI823471B (zh) | 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用 | |
JP2002234912A (ja) | リン酸結合性ポリマー及びそれを使用した製剤 | |
EP3784217A1 (en) | Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof | |
WO2011086577A2 (en) | Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131009 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5442116 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |